EMPA
- CAS No.
- 680590-49-2
- Chemical Name:
- EMPA
- Synonyms
- EMPA, CID 9981404;EMPA, 10 mM in DMSO;Hypocretin Receptor,EMPA,Orexin Receptor (OX Receptor),HCRT Receptor,inhibit,Inhibitor;N-Ethyl-2-((N-(6-methoxypyridin-3-yl)-2-methylphenyl)sulfonamido)-N-(pyridin-3-ylmethyl)acetamide;N-ETHYL-2-[(6-METHOXYPYRIDIN-3-YL)-(2-METHYLPHENYL)SULFONYLAMINO]-N-(PYRIDIN-3-YLMETHYL)ACETAMIDE;N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)-acetamide;Acetamide, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)-
- CBNumber:
- CB32695845
- Molecular Formula:
- C23H26N4O4S
- Molecular Weight:
- 454.54
- MDL Number:
- MOL File:
- 680590-49-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Boiling point | 660.7±65.0 °C(Predicted) |
|---|---|
| Density | 1.280±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol |
| form | Powder |
| pka | 4.77±0.10(Predicted) |
| color | white to light brown |
| InChI | 1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3 |
| InChIKey | KJPHTXTWFHVJIG-UHFFFAOYSA-N |
| SMILES | [S](=O)(=O)(N(CC(=O)N(CC)Cc3cnccc3)c2cnc(cc2)OC)c1c(cccc1)C |
| FDA UNII | VT87V86D7W |
| UNSPSC Code | 51111800 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P264-P270-P301+P312-P330-P501 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22 | |||||||||
| WGK Germany | 3 | |||||||||
| Storage Class | 11 - Combustible Solids | |||||||||
| Hazard Classifications | Acute Tox. 4 Oral | |||||||||
| NFPA 704 |
|
EMPA price More Price(40)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML0864 | EMPA ≥98% (HPLC) | 680590-49-2 | 5mg | $146 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML0864 | EMPA ≥98% (HPLC) | 680590-49-2 | 25mg | $473 | 2026-04-30 | Buy |
| Cayman Chemical | 29446 | EMPA ≥98% | 680590-49-2 | 5mg | $129 | 2026-04-30 | Buy |
| Cayman Chemical | 29446 | EMPA ≥98% | 680590-49-2 | 10mg | $205 | 2026-04-30 | Buy |
| Usbiological | 255245 | EMPA Asreported | 680590-49-2 | 10mg | $502 | 2026-06-03 | Buy |
EMPA Chemical Properties, Uses, Production
Description
EMPA is an orexin 2 receptor (OX2R) antagonist (Ki = 1.1 nM). It is selective for OX2R over OX1R (Ki = 900 nM). EMPA inhibits orexin-A- and orexin-B-induced calcium mobilization (IC50s = 8.8 and 7.9 nM, respectively) and increases orexin-A- and orexin-B-induced inositol phosphate accumulation (EC50s = 1.1 and 2.4 nM, respectively) in CHO(dHFr-) cells expressing recombinant human OX2R. It reduces spontaneous locomotor activity and orexin-B-induced hyperlocomotion in mice when administered at doses ranging between 10 and 300 mg/kg.
Uses
EMPA is a novel high-affinity, selective antagonist for the OX2 receptor.
in vivo
EMPA (1-300 mg/kg; i.p.) dose-dependently reverses this [Ala11,D-Leu15]orexin-B-induced hyperlocomotion without itself significantly affecting locomotor activity (LMA) in male NMRI mice[1].
EMPA (3-30 mg/kg; i.p.) induces a significant and dose-dependent reduction in the baseline LMA in france and male Wistar rats. EMPA (3-30 mg/kg; i.p.) demonstrates a clear dose-dependent inhibition of spontaneous activity as compared with vehicle-treated animals[1].
| Animal Model: | Male NMRI mice (20-30 g)[1] |
| Dosage: | 1, 3, 10, 30, 100, 300 mg/kg |
| Administration: | Injected i.p. at a volume of 10 mL/kg |
| Result: | Dose-dependently reversed this [Ala11,D-Leu15]orexin-B-induced hyperlocomotion without itself significantly affecting LMA. |
| Animal Model: | France and Male Wistar rats (196-237 g)[1] |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | Injected i.p. at a volume of 5 mL/kg |
| Result: | Induced a significant and dose-dependent reduction in the baseline LMA. Demonstrated a clear dose-dependent inhibition of spontaneous activity as compared with vehicle-treated animals. |
IC 50
OX2 Receptor
storage
Store at -20°C
References
[1] P MALHERBE. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor[J]. British Journal of Pharmacology, 2009, 156 8: 1326-1341. DOI: 10.1111/j.1476-5381.2009.00127.x
EMPA Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Shanghai TaoSu Biochemical Technology Co., Ltd. | 021-33632979 | info@tsbiochem.com | China | 8039 | 58 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Bide Pharmatech Ltd. | 400-164-7117 18317119277 | product02@bidepharm.com | China | 40000 | 60 |
| HangZhou YuHao Chemical Technology Co., Ltd. | 0571-82693216 | info@yuhaochemical.com | China | 1999 | 58 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4859 | 55 | |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Shanghai Chaolan Chemical Technology Center | QQ：65489617 13301690235 | Sales@ATKchemical.com | China | 9729 | 58 |
